Showing results (171-180 of 219) with videos related to
Sort By:
Pageof 22
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|April 17, 2012
Establishment and characterization of a novel chordoma cell line: CH22Xianzhe Liu, Gunnlager Petur Nielsen, Andrew E Rosenberg, et al.Sarcoma|August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C Widemann, Yao Lu, Denise Reinke, et al.Lancet (London, England)|February 15, 2016
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Sant Chawla, Robert G Maki, et al.Future Oncology (London, England)|February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcomaGregory M Cote, Sant P Chawla, George Demetri, et al.Plos Genetics|December 2, 2008
Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell linesEdwin Choy, Roman Yelensky, Sasha Bonakdar, et al.Nature Communications|March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.Cell Reports. Medicine|December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART MoleculeAlexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.Journal of Surgical Oncology|February 13, 2023
Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG OncologyMark L Kayton, Aaron R Weiss, Wei Xue, et al.Investigational New Drugs|May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumorsAlejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.Pageof 22